ixX pharma
ActiveSummary
ixX pharma has been active since 2005 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €6.9m and a net result of €1.7m. Equity is growing by ~11.7% per year across the filed fiscal years. Its solvency ranks better than 67% of 5071 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Checked score
Score 2025
Axes · tick = 2024
Profitability91▲+8
Solvency86=
Growth68▼-6
Track record100
Bankruptcy probability, 12 months
0.3%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €550,000 at 30 days acceptable
Liquidity ample (current ratio 2.18 against 2.38 in 2024; short-term debt: 38.6% and cash: 12% of total assets), and 38.6% of the assets are financed with debt.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
61.4%
Return on assets
15%
Age of the figures
9 mo
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 46
Relative position
BE, all sectors
reference
Wholesale trade (NACE 46)
about 21% more bankruptcies
← fewer bankruptcies
more bankruptcies →
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 31-08-2026, 31 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 10 filingsDeviation from the deadline
2025
31 d late
2024
27 d late
2023
36 d early
2022
20 d early
2021
11 d early
2020
26 d early
2019
24 d late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 2 days before the deadline; the sector median for financial year 2024 is 3 days before the deadline, and 39% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 20 July (4 of the last 5 filed years within 38 days of that day).
Companies Code · seven monthsPosition in the running window
30-09-2026 today31-12-2026 close31-07-2027 deadline
History
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Is the workforce growing, and do people stay?Employer check Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, full schema
Turnover
€11.6m▼ 8.9%
2024 · €12.8m
EBIT margin
18.9%▲ 4.6pp
2024 · 14.3%
Net result
€1.7m▲ 40.3%
2024 · €1.2m
Working capital
€5.1m▼ 7.8%
2024 · €5.6m
Trend over the years
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 46, Wholesale trade, each year against the same schema; no band under 30 filings. Dashed line: the median.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20212022202320242025
Turnover€9.6m€9.7m▲ 1.6%€10.4m▲ 7.3%€12.8m▲ 22.3%€11.6m▼ 8.9%
Operating result€591,816▼ 80.0%€522,802▼ 11.7%€1.5m▲ 183%€1.8m▲ 23.0%€2.2m▲ 20.6%
Net result€343,250within the sector's middle half▼ 84.2%€392,379within the sector's middle half▲ 14.3%€1.0mabove the sector's middle half▲ 157%€1.2mabove the sector's middle half▲ 19.4%€1.7mabove the sector's middle half▲ 40.3%
EBIT margin6.2%5.4%▼ 0.8pp14.2%▲ 8.8pp14.3%▲ 0.1pp18.9%▲ 4.6pp
Equity€5.4mabove the sector's middle half▲ 6.7%€4.8mabove the sector's middle half▼ 11.2%€5.1mabove the sector's middle half▲ 5.1%€6.3mabove the sector's middle half▲ 23.8%€6.9mabove the sector's middle half▲ 10.2%
Total assets€7.1mwithin the sector's middle half▼ 2.1%€7.4mwithin the sector's middle half▲ 3.6%€8.7mwithin the sector's middle half▲ 18.2%€10.3mwithin the sector's middle half▲ 17.7%€11.3mwithin the sector's middle half▲ 9.5%
Debt€1.7m▼ 22.7%€2.6m▲ 50.6%€3.7m▲ 42.8%€4.0m▲ 9.4%€4.3m▲ 8.4%
Working capital€4.7mabove the sector's middle half▲ 7.1%€4.2mabove the sector's middle half▼ 11.2%€4.3mabove the sector's middle half▲ 4.3%€5.6mabove the sector's middle half▲ 28.3%€5.1mabove the sector's middle half▼ 7.8%
Solvency76.1%above the sector's middle half▲ 6.3pp65.3%above the sector's middle half▼ 10.8pp58.1%within the sector's middle half▼ 7.2pp61.0%within the sector's middle half▲ 3.0pp61.4%within the sector's middle half▲ 0.4pp
Current ratio3.75above the sector's middle half▲ 0.722.62within the sector's middle half▼ 1.132.18within the sector's middle half▼ 0.442.38within the sector's middle half▲ 0.202.18within the sector's middle half▼ 0.21
Return on assets (ROA)4.8%within the sector's middle half▼ 24.9pp5.3%within the sector's middle half▲ 0.5pp11.6%above the sector's middle half▲ 6.2pp11.7%above the sector's middle half▲ 0.2pp15.0%above the sector's middle half▲ 3.3pp
Staff (FTE)20.6within the sector's middle half▲ 7.3%19within the sector's middle half▼ 7.8%21.8within the sector's middle half▲ 14.7%27.4within the sector's middle half▲ 25.7%26.3within the sector's middle half▼ 4.0%
above
within
below
the middle half (P25 to P75) of NACE 46, Wholesale trade, each year against the same schema; no band under 30 filings.
Why a figure moved sharply
- 2021 Net result -84% on 2020. The accounts now follow the full schema, last year the abbreviated schema.
Result per fiscal year
Operating resultNet result
After the dip in 2022 the operating result has climbed three years in a row; 2025 is 21% above 2024 and is the highest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €11.3m
Fixed assets
€1.8m ▲ 147%
Current assets
€9.5m ▼ 1.0%
Equity and liabilities €11.3m
Equity
€6.9m ▲ 10.2%
Debt
€4.3m ▲ 8.4%
Debt's share of the balance-sheet total falls from 39.0% to 38.6%. Equity and debt are higher.
Key figures and ratios
EBITDA
€2.3m▲
2024 · €1.9m
Cash flow
€1.8m▲
2024 · €1.3m
Quick ratio
1.69▼
2024 · 1.78
Debt to equity
0.63▼
2024 · 0.64
ROE
24.4%▲
2024 · 19.2%
Interest coverage
14.84▼
2024 · 16.42
Debt ≤ 1 year
€4.3m▲
2024 · €4.0m
Income taxes
€457,262▼
2024 · €580,120
Staff costs
€2.5m▼
2024 · €2.6m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 20,134 companies that looked in July 2024 the way this one looks now, 0.2% went bankrupt within 24 months and 95% are still going.
- Small
- 20 years or older
- solvency 30% or more
- a profit of 5% of the balance sheet or more
0.2%
went bankrupt
4.7%
stopped otherwise
95%
still going
For this company itself Checked computes a bankruptcy probability of 0.3% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,340 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 1.0% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 20,134 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Operating income70/76A | €9.6m | €9.3m | €10.7m | €12.2m | €12.5m | ▲ 2.5% |
| Turnover70 | €9.6m | €9.7m | €10.4m | €12.8m | €11.6m | ▼ 8.9% |
| Change in stocks of work in progress, finished goods and contracts in progress71 | - | -€486,060 | €138,743 | -€681,719 | - | - |
| Other operating income74 | €64,776 | €76,176 | €156,337 | €104,021 | €90,145 | ▼ 13.3% |
| Non-recurring operating income76A | €11,765 | - | - | €4,566 | €779,882 | ▲ 16,980% |
| Operating charges60/66A | €9.1m | €8.8m | €9.3m | €10.4m | €10.3m | ▼ 0.7% |
| Goods for resale, raw materials and consumables60 | €3.4m | €2.7m | €4.0m | €4.8m | €4.7m | ▼ 1.3% |
| Purchases600/8 | €3.6m | €2.3m | €4.8m | €4.6m | €4.4m | ▼ 5.5% |
| Change in stocks: decrease (increase)609 | -€202,479 | €372,246 | -€840,973 | €113,934 | €304,525 | ▲ 167% |
| Services and other goods61 | €3.0m | €3.7m | €2.9m | €2.9m | €3.0m | ▲ 3.2% |
| Remuneration, social security and pensions62 | €2.1m | €2.1m | €2.3m | €2.6m | €2.5m | ▼ 2.3% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €85,724 | €82,818 | €88,915 | €119,277 | €82,740 | ▼ 30.6% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | €71,838 | -€71,838 | - | - | - |
| Other operating charges640/8 | €15,600 | €11,792 | €13,055 | €12,939 | €9,333 | ▼ 27.9% |
| Non-recurring operating charges66A | €375,878 | €140,515 | €1,869 | - | - | - |
| Operating profit (loss)9901 | €591,816 | €522,802 | €1.5m | €1.8m | €2.2m | ▲ 20.6% |
| Financial income75/76B | €3 | €17,828 | €48,326 | €87,401 | €108,484 | ▲ 24.1% |
| Recurring financial income75 | €3 | €17,828 | €48,326 | €87,401 | €108,484 | ▲ 24.1% |
| Income from current assets751 | €0 | €14,835 | €48,325 | €87,061 | €108,482 | ▲ 24.6% |
| Other financial income752/9 | €3 | €2,992 | €1 | €340 | €1 | ▼ 99.6% |
| Financial charges65/66B | €29,512 | €41,081 | €106,273 | €121,951 | €155,736 | ▲ 27.7% |
| Recurring financial charges65 | €29,512 | €41,081 | €106,273 | €121,951 | €155,736 | ▲ 27.7% |
| Debt charges650 | €28,904 | €22,942 | €102,292 | €118,182 | €153,663 | ▲ 30.0% |
| Other financial charges652/9 | €608 | €18,139 | €3,980 | €3,769 | €2,072 | ▼ 45.0% |
| Profit (loss) for the period before taxes9903 | €562,307 | €499,548 | €1.4m | €1.8m | €2.1m | ▲ 20.3% |
| Income taxes67/77 | €219,058 | €107,168 | €412,488 | €580,120 | €457,262 | ▼ 21.2% |
| Taxes670/3 | €219,058 | €146,401 | €412,488 | €580,120 | €537,477 | ▼ 7.4% |
| Tax adjustments and reversals of tax provisions77 | - | €39,232 | - | - | €80,215 | - |
| Profit (loss) for the period9904 | €343,250 | €392,379 | €1.0m | €1.2m | €1.7m | ▲ 40.3% |
| Transfer from tax-exempt reserves789 | - | - | - | €1.0m | - | - |
| Transfer to tax-exempt reserves689 | €0 | - | - | - | - | - |
| Profit (loss) for the period to be appropriated9905 | €343,250 | €392,379 | €1.0m | €2.2m | €1.7m | ▼ 23.9% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €7.1m | €7.4m | €8.7m | €10.3m | €11.3m | ▲ 9.5% |
| Fixed assets21/28 | €769,705 | €678,475 | €749,428 | €732,047 | €1.8m | ▲ 147% |
| Intangible fixed assets21 | €10,016 | €4,538 | €402 | - | €4,725 | - |
| Tangible fixed assets22/27 | €725,704 | €670,371 | €747,461 | €730,482 | €103,770 | ▼ 85.8% |
| Land and buildings22 | €678,592 | €635,463 | €574,926 | €514,714 | - | - |
| Plant, machinery and equipment23 | €20,689 | €18,733 | €85,219 | €127,478 | €10,530 | ▼ 91.7% |
| Furniture and vehicles24 | €26,423 | €16,175 | €7,935 | €6,390 | - | - |
| Assets under construction and advance payments27 | - | - | €79,380 | €81,900 | €93,240 | ▲ 13.8% |
| Financial fixed assets28 | €33,985 | €3,565 | €1,565 | €1,565 | €1.7m | ▲ 108,626% |
| Affiliated companies280/1 | - | - | - | - | €1.7m | - |
| Participating interests280 | - | - | - | - | €1.7m | - |
| Other financial fixed assets284/8 | €33,985 | €3,565 | €1,565 | €1,565 | €1,565 | = |
| Amounts receivable and cash guarantees285/8 | €33,985 | €3,565 | €1,565 | €1,565 | €1,565 | = |
| Current assets29/58 | €6.4m | €6.7m | €8.0m | €9.6m | €9.5m | ▼ 1.0% |
| Stocks and contracts in progress3 | €3.1m | €2.3m | €3.2m | €2.4m | €2.1m | ▼ 12.6% |
| Stocks30/36 | €3.1m | €2.3m | €3.2m | €2.4m | €2.1m | ▼ 12.6% |
| Raw materials and consumables30/31 | €891,331 | €770,933 | €611,897 | - | - | - |
| Work in progress32 | €1.0m | €542,976 | €681,719 | - | - | - |
| Goods purchased for resale34 | €1.2m | €911,009 | €1.9m | €2.4m | €2.1m | ▼ 12.6% |
| Advance payments36 | - | €28,290 | - | - | - | - |
| Amounts receivable within one year40/41 | €1.9m | €3.5m | €3.6m | €5.8m | €6.0m | ▲ 3.1% |
| Trade receivables40 | €1.8m | €2.6m | €1.8m | €3.0m | €1.2m | ▼ 60.5% |
| Other amounts receivable41 | €26,770 | €934,137 | €1.8m | €2.8m | €4.8m | ▲ 69.2% |
| Cash at bank and in hand54/58 | €1.3m | €838,793 | €1.1m | €1.3m | €1.3m | ▲ 2.6% |
| Deferred charges and accrued income490/1 | €104,542 | €98,972 | €73,461 | €28,298 | €22,607 | ▼ 20.1% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €7.1m | €7.4m | €8.7m | €10.3m | €11.3m | ▲ 9.5% |
| Equity10/15 | €5.4m | €4.8m | €5.1m | €6.3m | €6.9m | ▲ 10.2% |
| Contributions10/11 | €512,449 | €512,449 | €599,949 | €599,949 | €599,949 | = |
| Capital10 | €490,000 | €490,000 | €490,000 | €490,000 | €490,000 | = |
| Issued capital100 | €490,000 | €490,000 | €490,000 | €490,000 | €490,000 | = |
| Outside capital11 | €22,449 | €22,449 | €109,949 | €109,949 | €109,949 | = |
| Share premium1100/10 | €22,449 | €22,449 | €109,949 | €109,949 | €109,949 | = |
| Reserves13 | €4.3m | €3.3m | €3.3m | €3.3m | €3.3m | = |
| Non-distributable reserves130/1 | €49,600 | €49,600 | €49,600 | €49,600 | €49,600 | = |
| Legal reserve130 | €49,600 | €49,600 | €49,600 | €49,600 | €49,600 | = |
| Tax-exempt reserves132 | €1.0m | €1.0m | €1.0m | - | - | - |
| Distributable reserves133 | €3.2m | €2.2m | €2.2m | €3.2m | €3.2m | = |
| Profit (loss) carried forward14 | €646,287 | €1.0m | €1.2m | €2.4m | €3.0m | ▲ 26.7% |
| Amounts payable17/49 | €1.7m | €2.6m | €3.7m | €4.0m | €4.3m | ▲ 8.4% |
| Amounts payable after more than one year17 | €0 | - | - | - | - | - |
| Financial debts170/4 | €0 | - | - | - | - | - |
| Other loans174 | €0 | - | - | - | - | - |
| Amounts payable within one year42/48 | €1.7m | €2.6m | €3.7m | €4.0m | €4.3m | ▲ 8.4% |
| Current portion of amounts payable after more than one year42 | €0 | - | - | - | - | - |
| Financial debts43 | €50,094 | €1.0m | €1.0m | €1.0m | €1.0m | = |
| Credit institutions430/8 | €50,094 | €1.0m | €1.0m | €1.0m | €1.0m | = |
| Trade debts44 | €1.1m | €1.2m | €1.2m | €2.3m | €1.1m | ▼ 51.3% |
| Suppliers440/4 | €1.1m | €1.2m | €1.2m | €2.3m | €1.1m | ▼ 51.3% |
| Taxes, remuneration and social security45 | €520,441 | €330,435 | €646,279 | €751,898 | €997,907 | ▲ 32.7% |
| Taxes450/3 | €261,678 | - | €207,431 | €318,129 | €549,366 | ▲ 72.7% |
| Remuneration and social security454/9 | €258,763 | €330,435 | €438,848 | €433,768 | €448,540 | ▲ 3.4% |
| Other amounts payable47/48 | €0 | - | €850,000 | - | €1.3m | - |
| Accrued charges and deferred income492/3 | €5,290 | - | €295 | - | - | - |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €343,250 | €392,379 | €1.0m | €1.2m | €1.7m | ▲ 40.3% |
| + Depreciation and write-downs630 | €85,724 | €82,818 | €88,915 | €119,277 | €82,740 | ▼ 30.6% |
| Operating cash flow (approximation) | €428,973 | €475,197 | €1.1m | €1.3m | €1.8m | ▲ 33.9% |
| Investment in fixed assets (approximation) | - | €8,412 | -€159,868 | -€101,896 | -€1.2m | ▼ 1,039% |
| Change in cash | - | -€479,615 | €233,847 | €240,422 | €34,403 | ▼ 85.7% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
31-08
NBB filing
Annual accounts filed
fiscal year 2025 · full schema · 31 days late
14-08
State Gazette act
Capital & shares · RestructuringMerger4 facts ▸
State Gazette act
Capital & shares · Restructuring
Merger4 facts ▸
- Board meeting, 17-07-2026
- Merger, verrichting gelijkgesteld met een fusie door overneming, jaarrekening afgesloten op 31 december 2025
- Other statement, inlichtingen aan aandeelhouders, ieder aandeelhouder heeft een kopie ontvangen van de twee voorstellen
- Other statement, beschrijving overgedragen vermogen, het geheel van haar activa en passiva, niets uitgezonderd noch voorbehouden
05-06
State Gazette act
RestructuringMerger · Declaration · Proposal11 facts ▸
State Gazette act
Restructuring
Merger · Declaration · Proposal11 facts ▸
- Merger, absorption, kan de fusie worden beslist door de bestuursorganen zonder goedkeuring van de algemene vergadering
- Board meeting, 27-05-2026
- Declaration, engagement to achieve merger, sous les conditions mentionnées ci-après
- Proposal, merger project submission, conditions prévues à l'article 12:53, §6 du CSA étant remplies, la fusion peut être décidée par les organes d'administration des soci…
- Declaration, acknowledgement of legal obligation to deposit and publish merger project, 6 semaines au moins avant l'assemblée générale extraordinaire
- Declaration, no special rights for shareholders or holders of other securities in the absorbed company
- Declaration, no special advantages for members of the management bodies of the merging companies
- Board meeting, 27-05-2026
- Board meeting, 27-05-2026
- Declaration, wettelijke verplichting tot neerlegging en publicatie van het fusievoorstel, ten minste 6 weken vóór de buitengewone algemene vergadering
- Declaration, wettelijke verplichting tot neerlegging en publicatie van het fusievoorstel, ten minste 6 weken vóór de buitengewone algemene vergadering
05-06
State Gazette act
Resignation: Benjamin Francq (day-to-day manager)Appointments: Michael Cosentino (day-to-day manager) and Marion Geffraye (day-to-day manager)4 facts ▸
State Gazette act
Resignation: Benjamin Francq (day-to-day manager)
Appointments: Michael Cosentino (day-to-day manager) and Marion Geffraye (day-to-day manager)4 facts ▸
- Board meeting, 29-04-2026
- Director resignation, Benjamin Francq (day-to-day manager)
- Director appointment, Michael Cosentino (day-to-day manager)
- Director appointment, Marion Geffraye (day-to-day manager)
2025
27-08
NBB filing
Annual accounts filed
fiscal year 2024 · full schema · 27 days late
2024
25-06
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
2023
31-12
Financial
Equity above €5mEq €5.1m ▲5.1%
6 profitable years in a row build equity to €5.1m.
11-07
NBB filing
Annual accounts filed
fiscal year 2022 · full schema
2022
20-07
NBB filing
Annual accounts filed
fiscal year 2021 · full schema
2021
31-12
Financial
Weakest financial yearnet €343,250 ▼84.2%
Net result drops to €343,250, the lowest in the series; recovery starts the following year.
05-07
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
31-12
Financial
Highest result since 2018net €2.2m ▲190%
Operating result €3.0m, net result €2.2m, both a record.
Show earlier events
31-12
Financial
Equity above €5mEq €5.1m ▲67.9%
3 profitable years in a row build equity to €5.1m.
24-08
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema · 24 days late
2019
01-07
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
27-07
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2017
30-05
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
3 of 16 acts read
About the unread acts
Of the 16 Belgian State Gazette acts we know for this company, 3 have been read. The other 13 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
2 office holders, last change in 2026
Day-to-day management 2
Marion Geffraye
CurrentDay-to-day manager · since 30-04-2026
Michael Cosentino
CurrentDay-to-day manager · since 30-04-2026
Derived from published Gazette acts. The CBE keeps the official list of function holders; we do not read it, so the two can differ.
See the function holders in the CBE →
Not every act has been read: a resignation may be missing here
13 of this company's 16 Belgian State Gazette acts have not been read yet. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Antwerpen · 1 establishment unit since 2005
Ground area
2.4 ha
Building footprint
2,702 m²
Parcel 11302A0095/00E008, Flanders. Linked by address, not a title deed.
101
companies at this address
See who is registered here
1 establishment unit
ixX pharma NV
since 20052.147.131.028
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 11302A0095/00E008 | Flanders | 2.4 ha | 1 · 2,702 m² | - |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Mandate history
3 people since 2026, 2 in office
- Day-to-day management
- began earlier
| Name | Functions and periods |
|---|---|
| Marion Geffraye |
|
| Michael Cosentino |
|
| Benjamin Francq |
|
Articles of association
Purpose
De ontwikkeling, productie, commercialisatie, opslag en distributie van farmaceutische producten en aanverwanten, en alles wat hiermee rechtstreeks of onrechtstreeks verband houdt…
Full purpose (10 activities)
- De ontwikkeling, productie, commercialisatie, opslag en distributie van farmaceutische producten en aanverwanten, en alles wat hiermee rechtstreeks of onrechtstreeks verband houdt
- Mandaten van bestuurder, afgevaardigd-bestuurder of vereffenaar van vennootschappen uitoefenen
- Zich borg stellen en goederen in pand geven of hypothekeren
- Alle verrichtingen doen die betrekking hebben op haar maatschappelijk doel of die van aard zijn om bij te dragen tot de ontwikkeling en vergemakkelijking ervan
- Door inbreng, fusie, inschrijving, deelneming, financiële tussenkomst, of op welke andere wijze, belangen nemen in elke bestaande of op te richten vennootschap of onderneming zowel in België als in het buitenland, waarvan de doelstellingen gelijkaardig of verwant zijn aan het hare of ermee samenhangend zijn
- Samenwerken met, deelnemen in, of op gelijk welke wijze, rechtstreeks of zijdelings, belangen nemen in ondernemingen van alleriei aard
- Alle verbintenissen aangaan
- Kredieten en leningen toestaan
- Zich voor derden borg stellen door haar goederen in hypotheek of in pand te geven inclusief de eigen handelszaak
- Alles doen wat verband houdt met bovengenoemd doel of kan bijdragen tot de realisatie ervan
Other statement
Geheelheid van de activa en passiva, goederen in hun huidige staat
2 more provisions on this in the deed
Accounting effect
01-01-2026
Custody of records
Zetel van de overnemende vennootschap, termijn voorzien in de wet
Power of attorney
2 provisions in the deed
Structure & network
Owners and holdings
1 owner · 1 holdingChain of control
- PONROY VITARMONYL BENELUX
- ixX pharma
Highest known parent: PONROY VITARMONYL BENELUX. The sources do not say who stands above it.
Owners 1
-
100%
Holdings 1
-
100%
According to the 2025 annual accounts of ixX pharma and those of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
2 current directorsThe network starts from this company’s directors. Other companies they run appear here as nodes.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, scroll to zoom.
Acquisitions and mergers
1 transactionTook over:BIOCYTE BENELUX
Recognitions · licences · registrations
Food safety, FASFC
1 siteAntwerpen2.147.131.028
Similar companies · same sector, comparable size
European Distribution Center Motiva
BE 0881.512.541
Wommelgem · Eq €6,926,725
Norgine
BE 0403.077.461
Leuven · Eq €6,956,923
BeMedico
BE 0432.727.589
Herzele · Eq €6,839,375
AMGEN
BE 0439.652.401
Machelen (Brab.) · Eq €6,817,251
GLOBIFER INTL
BE 0843.493.885
Kontich · Eq €7,043,061
Of 1,903 companies in sector 46460 we hold annual accounts for 1,126. 515 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPublic limited company
Founded26-04-2005
Fiscal year end31-12
Activities, NACEBEL 2025
46460Wholesale of pharmaceutical and medical goods
Contact
E-invoicing
Reachable via Peppol
Peppol ID
0208:0873490740
Registered
30-07-2025
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 30 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.